

pathogen, is exposed to the host immune system on the surface of free pathogen and/or pathogen-infected cells.--

~~10~~ ¹¹ A composition in accordance with Claim ~~10~~ wherein the microspheres further contain a pharmaceutically-acceptable adjuvant.--

~~3~~ ¹² The immunostimulating compositions described in claims 1 or 2 wherein the immunogenic substance is a native (oligomeric)HIV-1 envelope antigen that is conformationally stabilized by the polymer matrix and serves to elicit in animals the production of HIV specific cytotoxic T lymphocytes and antibodies preferentially reactive against native HIV-1 envelope antigen.--

[(Additionally, please add the following claims.)

A ¹³ *cont* ¹⁴ ~~Claim 13~~ A vaccine consisting of a blend of the immunostimulating compositions described in Claims 5 and 6.--

~~Claim 14~~ The immunostimulating compositions described in claim 6 employed as a parentally administered vaccine wherein the diameter size range of said vaccine microspheres lies between 1 nanometer and 20 microns.--

~~Claim 15~~ ¹³ The immunostimulating compositions described in claim 7 employed as a parentally administered vaccine wherein the diameter size range of said vaccine microspheres lies between 1 nanometer and 20 microns.--

~~Claim 16~~ ¹⁴ The immunostimulating compositions described in claim 6 employed as a mucosal vaccine wherein the size of more than 50% (by volume) of said vaccine microspheres is between 5 to 10 microns in diameter.

[In Claim 2, line 1, replace "Claim #1" with --Claim 1--;

6